NOVOZYMES A/S SPONS.ADR 1 (NZM) - Net Assets
Based on the latest financial reports, NOVOZYMES A/S SPONS.ADR 1 (NZM) has net assets worth €10.92 Billion EUR (≈ $12.77 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€16.52 Billion ≈ $19.32 Billion USD) and total liabilities (€5.60 Billion ≈ $6.55 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore NZM cash flow metrics to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €10.92 Billion |
| % of Total Assets | 66.09% |
| Annual Growth Rate | 60.37% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 206.07 |
NOVOZYMES A/S SPONS.ADR 1 - Net Assets Trend (2021–2025)
This chart illustrates how NOVOZYMES A/S SPONS.ADR 1's net assets have evolved over time, based on quarterly financial data. Also explore NOVOZYMES A/S SPONS.ADR 1 asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
The table below shows the annual net assets of NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025. For live valuation and market cap data, see market value of NOVOZYMES A/S SPONS.ADR 1.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €10.86 Billion ≈ $12.69 Billion |
-2.87% |
| 2024-12-31 | €11.18 Billion ≈ $13.07 Billion |
+480.39% |
| 2023-12-31 | €1.93 Billion ≈ $2.25 Billion |
+0.84% |
| 2022-12-31 | €1.91 Billion ≈ $2.23 Billion |
+16.35% |
| 2021-12-31 | €1.64 Billion ≈ $1.92 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NOVOZYMES A/S SPONS.ADR 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 634.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €11.16 Billion | 102.79% |
| Total Equity | €10.86 Billion | 100.00% |
NOVOZYMES A/S SPONS.ADR 1 Competitors by Market Cap
The table below lists competitors of NOVOZYMES A/S SPONS.ADR 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ABN Amro Group NV
AS:ABN
|
$24.13 Billion |
|
Willis Towers Watson PLC
NASDAQ:WTW
|
$24.15 Billion |
|
American Water Works
NYSE:AWK
|
$24.16 Billion |
|
NATURGY ENERGY ADR1/5/E01
F:GANA
|
$24.24 Billion |
|
Epiroc AB (publ)
ST:EPI-A
|
$24.03 Billion |
|
XPO Logistics Inc
NYSE:XPO
|
$24.01 Billion |
|
Sterling Construction Company Inc
NASDAQ:STRL
|
$24.00 Billion |
|
Repsol S.A
F:REPA
|
$23.97 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NOVOZYMES A/S SPONS.ADR 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,176,000,000 to 10,855,200,000, a change of -320,800,000 (-2.9%).
- Net income of 583,600,000 contributed positively to equity growth.
- Dividend payments of 402,700,000 reduced retained earnings.
- Share repurchases of 99,900,000 reduced equity.
- New share issuances of 44,000,000 increased equity.
- Other factors decreased equity by 445,800,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €583.60 Million | +5.38% |
| Dividends Paid | €402.70 Million | -3.71% |
| Share Repurchases | €99.90 Million | -0.92% |
| Share Issuances | €44.00 Million | +0.41% |
| Other Changes | €-445.80 Million | -4.11% |
| Total Change | €- | -2.87% |
Book Value vs Market Value Analysis
This analysis compares NOVOZYMES A/S SPONS.ADR 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.15x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.71x to 2.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €5.74 | €50.00 | x |
| 2022-12-31 | €6.71 | €50.00 | x |
| 2023-12-31 | €6.76 | €50.00 | x |
| 2024-12-31 | €23.98 | €50.00 | x |
| 2025-12-31 | €23.30 | €50.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NOVOZYMES A/S SPONS.ADR 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.38%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.04%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.51x
- Recent ROE (5.38%) is below the historical average (16.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 26.60% | 21.04% | 0.60x | 2.09x | €263.98 Million |
| 2022 | 26.57% | 20.94% | 0.63x | 2.02x | €307.65 Million |
| 2023 | 21.64% | 16.90% | 0.63x | 2.03x | €218.34 Million |
| 2024 | 2.74% | 7.98% | 0.25x | 1.36x | €-811.80 Million |
| 2025 | 5.38% | 14.04% | 0.25x | 1.51x | €-501.92 Million |
Industry Comparison
This section compares NOVOZYMES A/S SPONS.ADR 1's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $829,725,208
- Average return on equity (ROE) among peers: -429.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NOVOZYMES A/S SPONS.ADR 1 (NZM) | €10.92 Billion | 26.60% | 0.51x | $24.08 Billion |
| LIFELINE SPAC I OYJ A EO1 (0CD) | $2.38 Million | -65.24% | 41.76x | $261.36 Million |
| GRAPHENE MANUFACT.GROUP (0GF) | $2.03 Million | 0.00% | 1.43x | $185.36 Million |
| Orion Engineered Carbons SA (0OE) | $478.50 Million | 21.63% | 2.83x | $327.05 Million |
| COVESTRO AG SP.ADR 1/2 (1CO1) | $7.02 Billion | -9.18% | 0.92x | $11.11 Billion |
| H&R GmbH & Co. KGaA (2HRA) | $226.44 Million | 22.97% | 1.35x | $183.88 Million |
| LOOP INDUSTRIES DL-001 (3L9) | $367.00K | -4102.72% | 49.62x | $58.01 Million |
| Dotz Nano Ltd (57N) | $6.76 Million | -76.24% | 0.11x | $4.51 Million |
| TIDEWATER RENEWABLES LTD (7GZ) | $515.60 Million | 0.00% | 0.42x | $233.52 Million |
| DIRECTA PLUS PLC LS-0025 (88K) | $10.83 Million | -44.54% | 0.53x | $2.35 Million |
| TEKNA HOLDING ASA NK 2 (8VB) | $38.35 Million | -37.60% | 0.99x | $67.10 Million |
About NOVOZYMES A/S SPONS.ADR 1
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more